Debt to Equity Ratio Chart

View Debt to Equity Ratio for MTNB.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Debt to Equity Ratio Data

View and export this data back to 2014. Start Trial.
Date Value
June 30, 2026 0.0033
March 31, 2026 0.3934
December 31, 2025 0.2803
September 30, 2025 0.3613
June 30, 2025 0.3296
March 31, 2025 0.4329
December 31, 2024 0.3813
September 30, 2024 0.1946
June 30, 2024 0.1697
March 31, 2024 0.2335
December 31, 2023 0.1848
September 30, 2023 0.1602
June 30, 2023 0.1384
March 31, 2023 0.1223
December 31, 2022 0.1126
September 30, 2022 0.1096
June 30, 2022 0.1035
March 31, 2022 0.0958
December 31, 2021 0.0896
September 30, 2021 0.083
June 30, 2021 0.0558
March 31, 2021 0.0545
December 31, 2020 0.0588
September 30, 2020 0.0568
June 30, 2020 0.0548
Date Value
March 31, 2020 0.053
December 31, 2019 0.1279
September 30, 2019 0.1144
June 30, 2019 0.1103
March 31, 2019 0.108
December 31, 2018 0.0242
September 30, 2018 0.051
June 30, 2018 0.0124
March 31, 2018 0.0249
December 31, 2017 0.0248
September 30, 2017 0.0285
June 30, 2017 0.0046
March 31, 2017 0.0038
December 31, 2016 0.0202
September 30, 2016 0.0249
June 30, 2016 0.0101
March 31, 2016 0.00
December 31, 2015 0.0019
September 30, 2015 0.0047
June 30, 2015 0.0051
March 31, 2015 0.0016
December 31, 2014 0.00
September 30, 2014 0.00
June 30, 2014 0.00
March 31, 2014 0.00

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 0.0565
Alnylam Pharmaceuticals, Inc. 2.206
Anika Therapeutics, Inc. 0.1839
Savara, Inc. 0.2117
Vericel Corp. 0.2556